Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Stokes

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Autism and Developmental Disorders|August 7, 2022
Aging on the Autism Spectrum: Physical Activity in Individuals Receiving State Services in the United StatesDanielle A Waldron, Jeffrey Stokes, Caitlin E Coyle, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 5, 2025
Phenotype-Based Management of Recurrent Preschool Wheezing and AsthmaSejal Saglani, Anne M Fitzpatrick, Nikolaos G Papadopoulos, et al.
The Gerontologist|December 16, 2023
The Mediating Role of Proxy Respondents on the Relationship Between Cognitive Function and Self-Rated HealthAndrew G Alberth, Edward Alan Miller, Nina M Silverstein, et al.
The Journal of Allergy and Clinical Immunology|October 18, 2023
Prenatal vitamin D supplementation to prevent childhood asthma: 15-year results from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)Scott T Weiss, Hooman Mirzakhani, Vincent J Carey, et al.
Nature Communications|September 2, 2025
Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthmaCourtney L Gaberino, R Max Segnitz, Kimberly A Dill-McFarland, et al.
JAMA Pediatrics|July 14, 2025
Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children: A Secondary Analysis of a Randomized Clinical TrialMatthew C Altman, Tomasz Janczyk, Ryan C Murphy, et al.
Contemporary Clinical Trials|November 26, 2020
Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptationWanda Phipatanakul, David T Mauger, Theresa W Guilbert, et al.
Lancet (London, England)|August 14, 2022
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trialDaniel J Jackson, Leonard B Bacharier, Peter J Gergen, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Autism and Developmental Disorders|August 7, 2022
Aging on the Autism Spectrum: Physical Activity in Individuals Receiving State Services in the United StatesDanielle A Waldron, Jeffrey Stokes, Caitlin E Coyle, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 5, 2025
Phenotype-Based Management of Recurrent Preschool Wheezing and AsthmaSejal Saglani, Anne M Fitzpatrick, Nikolaos G Papadopoulos, et al.
The Gerontologist|December 16, 2023
The Mediating Role of Proxy Respondents on the Relationship Between Cognitive Function and Self-Rated HealthAndrew G Alberth, Edward Alan Miller, Nina M Silverstein, et al.
The Journal of Allergy and Clinical Immunology|October 18, 2023
Prenatal vitamin D supplementation to prevent childhood asthma: 15-year results from the Vitamin D Antenatal Asthma Reduction Trial (VDAART)Scott T Weiss, Hooman Mirzakhani, Vincent J Carey, et al.
Nature Communications|September 2, 2025
Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthmaCourtney L Gaberino, R Max Segnitz, Kimberly A Dill-McFarland, et al.
JAMA Pediatrics|July 14, 2025
Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children: A Secondary Analysis of a Randomized Clinical TrialMatthew C Altman, Tomasz Janczyk, Ryan C Murphy, et al.
Contemporary Clinical Trials|November 26, 2020
Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptationWanda Phipatanakul, David T Mauger, Theresa W Guilbert, et al.
Lancet (London, England)|August 14, 2022
Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trialDaniel J Jackson, Leonard B Bacharier, Peter J Gergen, et al.
Pageof 2